title: [Duration of treatment with etanercept and motives for discontinuation in a cohort of patients with rheumatic disease].
abstract: OBJECTIVE
  To evaluate the duration of etanercept (ETN) treatment and motives for discontinuation in our local cohort of patients with rheumatic pathology and compare them to the group with other biological treatments.
  
  
  METHODS
  Prospective observational cohort study. Disease diagnosis, start and end date and motive for discontinuation were recorded. Survival estimation was explored using Kaplan-Meier analysis with remaining patients censored at 1-year, 2-years and 5-years follow-up.
  
  
  RESULTS
  Ninety-two (45%) out of 205 patients started ETN treatment. Disease diagnoses recorded were: 48% rheumatoid arthritis, 33% ankylosing spondylitis, 11% psoriatic arthritis, 8% others (juvenile idiopathic arthritis, inflammatory bowel disease related spondylitis, SAPHO syndrome). 52% of patients are still on the drug. The motives for discontinuation were: inefficacy (65%), adverse events (33%) and lack of compliance (2%). Two patients discontinued ETN due to prolonged disease control. Adverse events were: infection (4 patients), post-injection skin reaction (3), uveitis (3), neoplasia (2) and others (3). Using a Kaplan-Meier analysis, at 1-year 64% (CI(95%) 54-74) of patients with ETN treatment had not experienced treatment failure, at 2-years, 59% (48-69) and at 5-years, 43% (30-52). With the rest of biologicals estimated survival was 61% (51-68), 47,5% (40-55) and 23% (10,5-32) respectively. Statistical analysis revealed significant differences (log-rank: P=.024; Breslow: P=.068; Tarone-Ware: P=.040).
  
  
  CONCLUSIONS
  In our cohort of patients treated with ETN the estimated survival was better than patients treated with other biological drugs at 1-year, 2-years and 5-years.
authors.affiliation: Reumatología, Hospital Marina Baixa, Villajoyosa, Alicante, España. senabre@hotmail.es
authors.forename: José Miguel
authors.initials: JM
authors.lastname: Senabre-Gallego
authors.forename: José
authors.initials: J
authors.lastname: Rosas-Gómez de Salazar
authors.forename: Gregorio
authors.initials: G
authors.lastname: Santos-Soler
authors.forename: Carlos
authors.initials: C
authors.lastname: Santos-Ramírez
authors.forename: Mabel
authors.initials: M
authors.lastname: Sánchez-Barrioluengo
authors.forename: Esteban
authors.initials: E
authors.lastname: Salas-Heredia
authors.forename: Xavier
authors.initials: X
authors.lastname: Barber-Vallés
authors.forename: Catalina
authors.initials: C
authors.lastname: Cano-Pérez
authors.forename: Núria
authors.initials: N
authors.lastname: Llahí-Vidal
authors.forename: Rosa
authors.initials: R
authors.lastname: Riestra-Juán
mesh_terms: D000068800:Etanercept; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D053208:Kaplan-Meier Estimate; D008297:Male; D009042:Motivation; D011446:Prospective Studies; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D012216:Rheumatic Diseases / Q000188:drug therapy* / Q000401:mortality / Q000523:psychology; D013997:Time Factors; D017211:Treatment Failure; D016312:Treatment Refusal
chemical_list: D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept